Felipe H. Cersosimo

Felipe H. Cersosimo
Send Message
View as an RSS Feed
  • How Apple Gets To $400 A Share  [View article]
    Jan 28, 2013. 04:17 AM | 1 Like Like |Link to Comment
  • How Apple Gets To $400 A Share  [View article]
    What is your point Mr. Apple? Does being new to a discussion forum disqualify me from expressing an opinion on a matter which I follow closely?
    Jan 25, 2013. 05:35 AM | 1 Like Like |Link to Comment
  • How Apple Gets To $400 A Share  [View article]
    My point is that the iPhone 5s or iPhone6 — whatever comes next — will tank. Nobody purchasing the iPhone 5 had any reason to believe they weren't making a logical decision, given the consistent Apple product releases up until that point. People who now own the iPhone 5 feel like they were duped. Look at the bigger picture, that is all I'm suggesting...
    Jan 14, 2013. 02:04 AM | 2 Likes Like |Link to Comment
  • How Apple Gets To $400 A Share  [View article]
    Investors were led to believe that iPhone 5 would be a worthy upgrade over its predecessors —largely due to the fact that Apple never releases anything without everybody knowing about it. Last year, many people expected the iPhone 5 but instead were left hanging with the 4S — though the iPhone 5 seems more like what the 4S should have been — a minor upgrade but nothing worth getting ones panties in a twist. The maps disaster made plenty of headlines, causing an even greater drop in consumer confidence. Many economists argue the rapid growth in consumer leverage has been the primary cause of corporate earnings growth in the past few decades and represents significant economic risk to the US economy. Yet in practice, that translates to a lack of consumer confidence — particularly in companies that lead them to believe that they need to wax $600 cash on their latest product and ask questions later. All good things must come to an end — Apple Inc. had to botch their bi-annual stranglehold on people’s wallets eventually — current share prices in the context of their recent tendency towards overhyped and arguably mediocre product releases smack of foolish leadership and proverbial fall from grace for the former tech titan.
    Jan 13, 2013. 03:27 PM | 2 Likes Like |Link to Comment
  • Facebook Investors: Your Nightmare Has Just Begun  [View article]
    Rank-and-file workers at four of the highest profile Internet companies that began selling shares in the past 16 months have collectively lost about $9 billion on paper since their initial public offerings, according to calculations by compensation researcher Equilar Inc. and The Wall Street Journal.
    Oct 7, 2012. 01:18 AM | Likes Like |Link to Comment
  • Miracle Improvement In ALS Patient Could Force Big Pharma To Get Serious On Stem Cell Therapy  [View article]
    You may love a stock, but I wouldn’t get too excited about somebody else’s tip, as you'll almost always be too late. Instead buy into companies with a history of superior earnings, barriers to entry in their field and a track record of wise investment.
    Sep 25, 2012. 09:38 AM | Likes Like |Link to Comment
  • The Next Big Growth Sector In Health Care: Stem Cell Therapy  [View article]
    Stem Cell Research is a wide open field, though it may be years before we have a clearly defined picture of which companies will lead the way. Whether or not one chooses to acknowledge it, it is indeed very early in the game from an investors and analysts alike. For every survivor there will be hundreds of failures, many of which some poor fool somewhere believed in at one point or another. That said, everybody has their favorites. We can’t go around crucifying individual contributors for choosing to focus on one, whilst leaving out others - at least not in this context.
    Sep 6, 2012. 02:48 AM | 1 Like Like |Link to Comment
  • Neuralstem Loses $0.08/Share in Q2  [View article]
    In lieu of the reported Q2 losses and resultant decline in overall investor interest, Neuralstem should not be written off too easily. Playing the biotech game is not for the faint of heart, and for those willing to stomach the ups and downs of small-cap pharma, Neuralstem still has plenty to offer as part of a broad and diversified biotech strategy.
    Sep 5, 2012. 06:48 PM | Likes Like |Link to Comment